Watch WHWK. Know when insiders buy.
One email the day a filing lands. Free.
WHWK
Whitehawk Therapeutics, Inc.
3.70
−0.06 −1.60%
USD · close Oct 2
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
100
PASS · shorts 100
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $210.9MP/E —DIV YIELD —FCF YIELD -32.88%REV TTM $0 −100.0%NET INCOME −$79.8MNET CASH —52W 1.96 – 5.10SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $0 | — | — | −$18.1M | −$16.6M | — | -0.20 | −$14.5M | $0 | −$14.5M | Aug 6 |
| Q1 2026 · Mar 31 | $0 | −100.0% | — | −$23.5M | −$22.2M | −130.4% | -0.32 | −$22.2M | $0 | −$22.2M | Aug 6 |
| Q4 2025 · Dec 31derived | $0 | −100.0% | — | −$24.9M | −$23.3M | — | -0.37 | −$17.2M | $0 | −$17.2M | Mar 12 |
| Q3 2025 · Sep 30 | $0 | −100.0% | — | −$19.5M | −$17.7M | — | -0.26 | −$15.4M | $0 | −$15.4M | Nov 6 |
| Q2 2025 · Jun 30 | $0 | −100.0% | — | −$54.7M | −$52.6M | — | -0.76 | −$53M | $1K | −$53M | Aug 6 |
| Q1 2025 · Mar 31 | $7.1M | +33.5% | 89.4% | −$15.2M | $73M | — | 1.83 | −$11.9M | $551K | −$12.4M | Aug 6 |
| Q4 2024 · Dec 31derived | $7.2M | +14.4% | 89.1% | −$18.9M | −$18.3M | — | -0.68 | −$15.1M | $186K | −$15.2M | Mar 12 |
| Q3 2024 · Sep 30 | $7.2M | +21.0% | 88.9% | −$13.4M | −$12.5M | — | -0.46 | −$15.7M | $188K | −$15.9M | Nov 6 |
| Q2 2024 · Jun 30 | $6.2M | — | 87.4% | −$15.6M | −$14.6M | — | -0.54 | −$9.2M | $541K | −$9.7M | Nov 6 |
| Q1 2024 · Mar 31 | $5.4M | — | 87.8% | −$19.5M | −$18.3M | — | -0.68 | −$19.7M | $739K | −$20.4M | Nov 6 |
| Q4 2023 · Dec 31derived | $6.3M | — | 85.3% | −$17.7M | −$16.3M | — | -0.60 | −$9.6M | $816K | −$10.5M | Mar 28 |
| Q3 2023 · Sep 30 | $6M | — | 88.3% | −$17.8M | −$16.3M | — | -0.60 | −$12M | $1.1M | −$13M | Nov 6 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $7.1M | 89.4% | −$114.4M | −$20.6M | -288.3% | -0.33 | −$97.4M | $552K | −$98M | — | — |
| FY2024 · to Dec 31 | $26M | 88.4% | −$67.5M | −$63.7M | -245.1% | -2.36 | −$59.5M | $1.7M | −$61.2M | — | — |
| FY2023 · to Dec 31 | $24.4M | 88.5% | −$71.9M | −$65.8M | -270.0% | -2.44 | −$59.7M | $4M | −$63.6M | — | — |
| FY2022 · to Dec 31 | $15.2M | 91.2% | −$62.7M | −$60.5M | -397.7% | -2.69 | −$49.6M | $444K | −$50.1M | — | $0 |
| FY2021 · to Dec 31 | $14M | 100.0% | −$111.2M | −$110.1M | -786.4% | -12.41 | −$22.4M | $46K | −$22.5M | — | $4.4M |
| FY2020 · to Dec 31 | $14M | — | −$2.5M | −$3.5M | -24.8% | -1.76 | −$12.7M | $19K | −$12.7M | — | — |
Every number comes from Whitehawk Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.